Population Pharmacokinetics and Safety of Piperacillin-Tazobactam Extended Infusions in Infants and Children | Zendy

Céline Thibault | Zendy; Jean Lavigne | Zendy; Catherine Litalien | Zendy; Nastya Kassir | Zendy; Yves Théorêt | Zendy; Julie Autmizguine | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Population Pharmacokinetics and Safety of Piperacillin-Tazobactam Extended Infusions in Infants and Children

Author(s) -

Céline Thibault,

Jean Lavigne,

Catherine Litalien,

Nastya Kassir,

Yves Théorêt,

Julie Autmizguine

Publication year - 2019

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01260-19

Subject(s) - piperacillin/tazobactam , pharmacokinetics , piperacillin , medicine , population pharmacokinetics , tazobactam , population , anesthesia , intensive care medicine , pharmacology , pediatrics , environmental health , biology , genetics , bacteria , pseudomonas aeruginosa

Piperacillin-tazobactam (TZP) is frequently used to treat severe hospital-acquired infections in children. We performed a single-center, pharmacokinetic (PK) trial of TZP in children ranging in age from 2 months to 6 years from various clinical subpopulations.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research